Partner With Us

Where Collaboration Drives Discovery

At Delta4 we’re always looking for key partnerships that are mutually beneficial. Combining our strengths with those of your pharmaceutical company, university, research organization, etc., we can accelerate progress and accomplish more together.

Co-development of assets with preclinical and clinical stage biotech and pharma companies

Active involvement in (EU)-funded research consortia with academic and clinical partners across Europe

How We Contribute

In every collaboration, we contribute deep computational expertise in disease biology and drug mechanisms of action, working alongside your team to generate insights that drive programs forward.

Computational modeling of disease pathobiology

Drug mechanism of action analysis

Asset prioritization for preclinical and clinical testing

Biomarker and indication hypothesis generation

Grant proposal development and consortium participation

Integration of partner-provided omics, preclinical, and clinical data

Collaboration

Who We Partner With

Big Pharma

Optimize, reposition, or rescue clinical and preclinical assets.

Biotech Companies

Prioritize the right targets, indications, and experiments to move your program forward with confidence.

Academic Groups/Institutions

Translate your discoveries into clinically relevant hypotheses and real-world therapeutic opportunities.

(Contract) Research Organizations

Enhance your service offerings with data-driven insights that guide your clients' development decisions.

Patient Organizations

Identify new therapeutic opportunities to bring meaningful treatment options to patients faster.

What Our Partners Say

We are delighted to count Paul Perco, Computational Biology Lead at Delta4, among the members of the management committee of the PerMediK EU COST Action. Under his leadership, Delta4 has made significant contributions to advancing data-driven approaches for investigating kidney disease at the molecular level, resulting in multiple high-quality publications. Notably, several of these initiatives were fostered through short-term scientific visits, reflecting Delta4’s commitment to mentoring early-stage researchers. The team’s collaborative mindset, scientific rigor, and ability to integrate multidisciplinary expertise make Delta4 an exceptionally valuable partner in every biomedical research project.

Delta4 is a valued partner of the PROMOTE project. Their advanced computational workflows for prioritizing drug combinations, particularly in the context of synthetic lethal interactions, have made significant contributions to the project’s progress and scientific impact. We are especially pleased that several doctoral candidates will complete secondments in this industrial doctoral training network at Delta4, where they will gain hands-on experience in multi-omics data analysis and AI/ML driven approaches to digital drug discovery.

We are pleased to have Paul Perco, Computational Biology Lead at Delta4, as a member of the management committee of the KidneyHealth EU COST Action. He brings deep expertise in bioinformatics, disease modeling, translational research, and data-driven drug discovery. Paul and his team at Delta4 play a key role in advancing the project’s scientific and strategic objective, and their contributions are instrumental to its success.

Most partnerships begin with a single conversation.

Strategic Partnerships

Driving progress in precision medicine through collaboration.

Commercial Partnership

Co-Development with 4P-Pharma

Novel Therapies for PBC & PSC

Delta4 and 4P-Pharma are jointly developing novel therapeutic candidates for primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), two progressive cholestatic liver diseases with high unmet medical need. Using its Hyper-C platform, Delta4 leads computational compound discovery, candidate prioritization, and mechanism-of-action analysis to identify first-in-class treatment options. Selected compounds from Delta4’s computational ranking are currently being evaluated by 4P-Pharma in preclinical efficacy studies. Initial preclinical results are available. This long-term collaboration combines AI-driven discovery with translational pharmacology to advance disease-modifying therapies toward the clinic.

Fast facts

Program: 4P-Pharma (France)
Indications: Primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC)
Delta4 role: Lead generation, compound ranking, mechanism-of-action analysis
4P-Pharma role: Pharmacology, PK, toxicology, preclinical development
Status: Compounds identified; first preclinical results available
Duration: 2020 – 2025

Academic Partnership

PICKED

Personalized Medicine in Chronic Kidney Disease

PICKED is an EU-funded Marie Skłodowska-Curie Doctoral Network advancing personalized medicine in chronic kidney disease (CKD), with a focus on the transition from acute kidney injury (AKI) to CKD. Delta4 plays a central role by uncovering molecular mechanisms of disease progression using its proprietary Hyper-C platform and AI-driven drug repurposing workflows. By analyzing large-scale, multi-omics datasets, Delta4 identifies biomarkers, therapeutic targets, and optimized treatment strategies across disease stages. Close collaboration with experimental and clinical partners enables rapid validation of computational predictions using unpublished consortium data. Together, the consortium accelerates translation of systems-level insights into clinically relevant decision support for nephrology.

Fast facts

Program: MSCA Doctoral Network (Horizon Europe)
Focus: CKD, AKI-to-CKD transition, personalized pharmacotherapy
Delta4 role: Computational disease modeling, biomarker discovery, drug target discovery, drug repurposing
Technology: Hyper-C platform, AI-driven multi-omics analysis
Consortium: 10 European institutions + 9 associated partners
Duration: Oct 2024 – Sept 2028

Academic Partnership

PROMOTE

Omics-Oriented Intervention in Prostate Cancer

PROMOTE is an EU-funded Marie Skłodowska-Curie Doctoral Network focused on improving clinical management of prostate cancer through omics technologies and artificial intelligence. The project addresses disease progression from early-stage prostate cancer to advanced and metastatic disease, where prognosis remains poor and treatment options are limited. Delta4 contributes AI-powered systems biology analyses using its Hyper-C platform to translate multi-omics data into actionable biomarkers and therapeutic strategies. A central focus of Delta4’s work is the investigation of synthetic lethality to identify gene interactions and rational drug combinations that selectively target cancer cells. Through close collaboration with academic, clinical, and industry partners, PROMOTE accelerates the development of non-invasive diagnostics and molecularly driven therapies for personalized prostate cancer treatment.

Fast facts

Program: MSCA Doctoral Network (Horizon Europe)
Focus: Prostate cancer progression, omics, AI-driven intervention
Delta4 role: Computational disease modeling, synthetic lethality, drug combination discovery
Technology: Hyper-C platform, AI-based multi-omics integration
Consortium: 13 partners across Greece, Austria, Portugal, Germany & Spain
Duration: Sept 2024 – Aug 2028

Academic Partnership

PerMediK

Personalized Medicine in Chronic Kidney Disease

PerMediK is an EU-funded COST Action focused on advancing personalized medicine in chronic kidney disease (CKD) through coordinated use of multidimensional omics data and systems biology. Delta4 joined the initiative in 2023, with its Computational Biology Lead representing Austria on the PerMediK Management Committee. The action brings together a pan-European network of experts from nephrology, bioinformatics, biomarker research, and drug development to overcome fragmentation in CKD research. Delta4 contributes computational disease modeling expertise to support harmonized data integration, biomarker translation, and clinically relevant interpretation of large-scale molecular datasets. By fostering structured collaboration and knowledge exchange, PerMediK accelerates the path from Big Data to actionable insights in CKD.

Fast facts

Program: COST Action (CA21165)
Focus: Personalized medicine in chronic kidney disease (CKD)
Delta4 role: Management Committee member, computational modeling expertise
Approach: Multi-omics integration, systems biology, data harmonization
Consortium: Pan-European academic, clinical, and industry network
Duration: Jan 2023 – Jan 2027

Our Partners & Clients

It’s an honor and a privilege to be working with the best of the best.

Frequently Asked Questions

Everything you need to know about working with Delta4.

How does a collaboration with you typically work?

Our role in co-development projects is to provide computational modeling that helps prioritize assets for preclinical and clinical testing in collaboration with partners. In addition, we contribute expertise in disease pathobiology and drug mechanisms of action to support drug discovery, including participation in grant proposal development and publicly funded research consortia.

What do we need to provide to get started?

Depending on the specific use case, the starting point is always a specific asset: either a disease of interest, or a drug target or compound, or a biomarker. Existing data (e.g. omics, preclinical, or clinical insights) are helpful and can be integrated into analysis workflows, but it are not required to generate data-driven hypotheses on indications, mechanisms, or biomarkers.

What kind of outcomes can we expect?

The output is a structured report presenting prioritized targets, new indication hypotheses, biomarker strategies, or repositioning opportunities—always delivered with a clear rationale to support experimental validation or strategic decisions.

How is this different from traditional CRO or consulting services?

We go beyond execution or high-level advice by delivering data-driven, mechanistically grounded hypotheses that directly inform your next decisions—bridging the gap between raw data and actionable strategy.